deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT00718666

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination

Sponsor: GlaxoSmithKline

Updated 9 times since 2017 Last updated: Jun 11, 2019 Started: Oct 20, 2008 Primary completion: Nov 13, 2013 Completion: Mar 28, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Infections, Meningococcal, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotCompleted~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshotCompleted~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshotCompleted~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Phase: PHASE2_PHASE3PHASE2

  5. Feb 2019 — Jul 2019 [monthly]

    Completed PHASE2_PHASE3

    Phase: PHASE2PHASE2_PHASE3

Show 4 earlier versions
  1. Sep 2018 — Feb 2019 [monthly]

    Completed PHASE2

  2. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .